Cargando…
Expression of Programmed Death Ligand1 (PD-L1) in Gastric Carcinoma (Histopathological and Immunohistochemical Study)
OBJECTIVES: To evaluate immunohistochemical expression of PD-L1 in cases of gastric adenocarcinoma. To correlate PD-L1 immuno-histochemical expression with other available clinico-pathological parameters such as age, sex, grade, stage, lymph node (L.N) metastasis and others. MATERIAL AND METHODS: Th...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676478/ https://www.ncbi.nlm.nih.gov/pubmed/37505759 http://dx.doi.org/10.31557/APJCP.2023.24.7.2295 |
_version_ | 1785141289859153920 |
---|---|
author | Ali, Safa Mohammed Helmy, Dina Omar Abdelhamid, Hanan Soliman Eldin Abdelmagid Mahmoud, Mona Salah |
author_facet | Ali, Safa Mohammed Helmy, Dina Omar Abdelhamid, Hanan Soliman Eldin Abdelmagid Mahmoud, Mona Salah |
author_sort | Ali, Safa Mohammed |
collection | PubMed |
description | OBJECTIVES: To evaluate immunohistochemical expression of PD-L1 in cases of gastric adenocarcinoma. To correlate PD-L1 immuno-histochemical expression with other available clinico-pathological parameters such as age, sex, grade, stage, lymph node (L.N) metastasis and others. MATERIAL AND METHODS: The present retrospective study retrieved the data and archived paraffin blocks of 60 cases of Gastric carcinoma. Immunohistochemical evaluation was done to assess the expressions of PD-L1 in the tumor cells (TC), tumor infiltrated lymphocytes (TILs) and combined positive score (CPS). RESULTS: TC PD-L1 expression was detected in 56.7% of cases, TILs PD-L1 expression was detected in 53.3 % of cases and CPS PD-L1 expression was detected in 63.3% of case, with no statistically significant correlation with clinico-pathological parameters except TILs PD-L1 expression showed statistically significant correlation with positive TILs (P value ˂0.019). CONCLUSION: Our findings supported the expression of PD-L1 by TC, TILs, and CPS in gastric cancer, with increased expression in a subpopulation of TILs rich in PD-L1 identifying them as potential targets for PD-1/PD-L1 therapy. |
format | Online Article Text |
id | pubmed-10676478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-106764782023-03-01 Expression of Programmed Death Ligand1 (PD-L1) in Gastric Carcinoma (Histopathological and Immunohistochemical Study) Ali, Safa Mohammed Helmy, Dina Omar Abdelhamid, Hanan Soliman Eldin Abdelmagid Mahmoud, Mona Salah Asian Pac J Cancer Prev Research Article OBJECTIVES: To evaluate immunohistochemical expression of PD-L1 in cases of gastric adenocarcinoma. To correlate PD-L1 immuno-histochemical expression with other available clinico-pathological parameters such as age, sex, grade, stage, lymph node (L.N) metastasis and others. MATERIAL AND METHODS: The present retrospective study retrieved the data and archived paraffin blocks of 60 cases of Gastric carcinoma. Immunohistochemical evaluation was done to assess the expressions of PD-L1 in the tumor cells (TC), tumor infiltrated lymphocytes (TILs) and combined positive score (CPS). RESULTS: TC PD-L1 expression was detected in 56.7% of cases, TILs PD-L1 expression was detected in 53.3 % of cases and CPS PD-L1 expression was detected in 63.3% of case, with no statistically significant correlation with clinico-pathological parameters except TILs PD-L1 expression showed statistically significant correlation with positive TILs (P value ˂0.019). CONCLUSION: Our findings supported the expression of PD-L1 by TC, TILs, and CPS in gastric cancer, with increased expression in a subpopulation of TILs rich in PD-L1 identifying them as potential targets for PD-1/PD-L1 therapy. West Asia Organization for Cancer Prevention 2023 /pmc/articles/PMC10676478/ /pubmed/37505759 http://dx.doi.org/10.31557/APJCP.2023.24.7.2295 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | Research Article Ali, Safa Mohammed Helmy, Dina Omar Abdelhamid, Hanan Soliman Eldin Abdelmagid Mahmoud, Mona Salah Expression of Programmed Death Ligand1 (PD-L1) in Gastric Carcinoma (Histopathological and Immunohistochemical Study) |
title | Expression of Programmed Death Ligand1 (PD-L1) in Gastric Carcinoma (Histopathological and Immunohistochemical Study) |
title_full | Expression of Programmed Death Ligand1 (PD-L1) in Gastric Carcinoma (Histopathological and Immunohistochemical Study) |
title_fullStr | Expression of Programmed Death Ligand1 (PD-L1) in Gastric Carcinoma (Histopathological and Immunohistochemical Study) |
title_full_unstemmed | Expression of Programmed Death Ligand1 (PD-L1) in Gastric Carcinoma (Histopathological and Immunohistochemical Study) |
title_short | Expression of Programmed Death Ligand1 (PD-L1) in Gastric Carcinoma (Histopathological and Immunohistochemical Study) |
title_sort | expression of programmed death ligand1 (pd-l1) in gastric carcinoma (histopathological and immunohistochemical study) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676478/ https://www.ncbi.nlm.nih.gov/pubmed/37505759 http://dx.doi.org/10.31557/APJCP.2023.24.7.2295 |
work_keys_str_mv | AT alisafamohammed expressionofprogrammeddeathligand1pdl1ingastriccarcinomahistopathologicalandimmunohistochemicalstudy AT helmydinaomar expressionofprogrammeddeathligand1pdl1ingastriccarcinomahistopathologicalandimmunohistochemicalstudy AT abdelhamidhanansoliman expressionofprogrammeddeathligand1pdl1ingastriccarcinomahistopathologicalandimmunohistochemicalstudy AT eldinabdelmagidmahmoudmonasalah expressionofprogrammeddeathligand1pdl1ingastriccarcinomahistopathologicalandimmunohistochemicalstudy |